374 related articles for article (PubMed ID: 25897856)
1. Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy.
Parhi P; Sahoo SK
J Colloid Interface Sci; 2015 Aug; 451():198-211. PubMed ID: 25897856
[TBL] [Abstract][Full Text] [Related]
2. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy.
Acharya S; Dilnawaz F; Sahoo SK
Biomaterials; 2009 Oct; 30(29):5737-50. PubMed ID: 19631377
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells.
Eloy JO; Petrilli R; Brueggemeier RW; Marchetti JM; Lee RJ
Anticancer Agents Med Chem; 2017; 17(1):48-56. PubMed ID: 27225450
[TBL] [Abstract][Full Text] [Related]
4. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional nanoparticle-EpCAM aptamer bioconjugates: a paradigm for targeted drug delivery and imaging in cancer therapy.
Das M; Duan W; Sahoo SK
Nanomedicine; 2015 Feb; 11(2):379-89. PubMed ID: 25240596
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells.
Taheri A; Dinarvand R; Atyabi F; Ghahremani MH; Ostad SN
Eur J Pharm Sci; 2012 Sep; 47(2):331-40. PubMed ID: 22771547
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional Bioconjugate for Cancer Cell-Targeted Theranostics.
Du W; Yuan Y; Wang L; Cui Y; Wang H; Xu H; Liang G
Bioconjug Chem; 2015 Dec; 26(12):2571-8. PubMed ID: 26580576
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-modified DM1-loaded nanoparticles for HER2
Rong L; Zhou S; Liu X; Li A; Jing T; Liu X; Zhang Y; Cai S; Tang X
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1708-1718. PubMed ID: 29069935
[TBL] [Abstract][Full Text] [Related]
10. [Preclinical application of MR and fluorescent dual-modality imaging combined with photothermal therapy in HER-2 positive breast cancer].
Luo XJ; Li J; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):587-593. PubMed ID: 30139028
[No Abstract] [Full Text] [Related]
11. Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
Dragowska WH; Verreault M; Yapp DT; Warburton C; Edwards L; Ramsay EC; Huxham LA; Minchinton AI; Gelmon K; Bally MB
Breast Cancer Res Treat; 2007 Dec; 106(3):319-31. PubMed ID: 17347776
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy.
Acevedo-Gadea C; Hatzis C; Chung G; Fishbach N; Lezon-Geyda K; Zelterman D; DiGiovanna MP; Harris L; Abu-Khalaf MM
Breast Cancer Res Treat; 2015 Feb; 150(1):157-67. PubMed ID: 25687356
[TBL] [Abstract][Full Text] [Related]
13. Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity.
Houdaihed L; Evans JC; Allen C
Pharm Res; 2020 Jan; 37(3):39. PubMed ID: 31965330
[TBL] [Abstract][Full Text] [Related]
14. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
Carraway H; Hidalgo M
Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
[TBL] [Abstract][Full Text] [Related]
15. Targeted co-delivery of polypyrrole and rapamycin by trastuzumab-conjugated liposomes for combined chemo-photothermal therapy.
Nguyen HT; Tran TH; Thapa RK; Phung CD; Shin BS; Jeong JH; Choi HG; Yong CS; Kim JO
Int J Pharm; 2017 Jul; 527(1-2):61-71. PubMed ID: 28528212
[TBL] [Abstract][Full Text] [Related]
16. Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy.
Marcinkowska M; Stanczyk M; Janaszewska A; Sobierajska E; Chworos A; Klajnert-Maculewicz B
Pharm Res; 2019 Sep; 36(11):154. PubMed ID: 31482205
[TBL] [Abstract][Full Text] [Related]
17. Bifunctional Elastin-like Polypeptide Nanoparticles Bind Rapamycin and Integrins and Suppress Tumor Growth in Vivo.
Dhandhukia JP; Shi P; Peddi S; Li Z; Aluri S; Ju Y; Brill D; Wang W; Janib SM; Lin YA; Liu S; Cui H; MacKay JA
Bioconjug Chem; 2017 Nov; 28(11):2715-2728. PubMed ID: 28937754
[TBL] [Abstract][Full Text] [Related]
18. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
19. Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo.
Shi P; Aluri S; Lin YA; Shah M; Edman M; Dhandhukia J; Cui H; MacKay JA
J Control Release; 2013 Nov; 171(3):330-8. PubMed ID: 23714121
[TBL] [Abstract][Full Text] [Related]
20. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles.
Anhorn MG; Wagner S; Kreuter J; Langer K; von Briesen H
Bioconjug Chem; 2008 Dec; 19(12):2321-31. PubMed ID: 18937508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
